Patents by Inventor Ozkan Yalkinoglu
Ozkan Yalkinoglu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11149089Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: GrantFiled: October 2, 2018Date of Patent: October 19, 2021Assignee: Ablynx N.V.Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
-
Publication number: 20190119393Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: ApplicationFiled: October 2, 2018Publication date: April 25, 2019Applicant: Ablynx N.V.Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
-
Patent number: 10138302Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: GrantFiled: September 24, 2012Date of Patent: November 27, 2018Assignee: Ablynx N.V.Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
-
Publication number: 20150050268Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: ApplicationFiled: September 24, 2012Publication date: February 19, 2015Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Ozkan Yalkinoglu
-
Publication number: 20140212417Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.Type: ApplicationFiled: September 24, 2012Publication date: July 31, 2014Applicant: Ablynx N.V.Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
-
Publication number: 20140194318Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.Type: ApplicationFiled: March 18, 2014Publication date: July 10, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Õzkan Yalkinoglu, Gerhard König, Denis F. Hochstrasser, Jean-Charles Sanchez, Odile Carrette
-
Patent number: 8772042Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.Type: GrantFiled: May 2, 2011Date of Patent: July 8, 2014Assignee: Bayer Intellectual Property GmbHInventors: Özkan Yalkinoglu, Gerhard König, Denis Francois Hochstrasser, Jean-Charles Sanchez, Odile Carrette
-
Publication number: 20120016205Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.Type: ApplicationFiled: May 2, 2011Publication date: January 19, 2012Applicant: BAYER HEALTHCARE AGInventors: Õzkan Yalkinoglu, Gerhard Kõnig, Denis Francois Hochstrasser, Jean-Charles Sanchez, Odile Carrette
-
Patent number: 7202243Abstract: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.Type: GrantFiled: June 25, 2003Date of Patent: April 10, 2007Assignee: Bayer HealthCare AGInventors: Martin Hendrix, David Brückner, Arno Friedl, Irene Gerlach, Volker Hinz, Jörg Keldenich, Frank Mauler, Maria Niewöhner, legal representative, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteegen, Özkan Yalkinoglu, Ulrich Niewöhner, deceased
-
Publication number: 20060240561Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.Type: ApplicationFiled: August 11, 2003Publication date: October 26, 2006Inventors: Ozkan Yalkinoglu, Gerhard Konig, Denis Hochstrasser, Jean-Charles Sanchez, Odile Carrette
-
Publication number: 20060166992Abstract: The invention relates to new heterocyclically substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.Type: ApplicationFiled: June 25, 2003Publication date: July 27, 2006Applicant: Bayer Healthcare A GInventors: Martin Hendrix, David Bruckner, Arno Friedl, Irene Gerlach, Volker Hinz, Jorg Keldenich, Frank Mauler, Ulrich Niewohner, Maria Niewohner, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteeger, Ozkan Yalkinoglu
-
Publication number: 20060166993Abstract: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.Type: ApplicationFiled: June 25, 2003Publication date: July 27, 2006Applicant: Bayer Healthcare AGInventors: Martin Hendrix, David Bruckner, Arno Friedl, Irene Gerlach, Volker Hinz, Jorg Keldenich, Frank Mauler, Ulrich Niewohner, Maria Niewohner, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteegen, Ozkan Yalkinoglu
-
Patent number: 5935983Abstract: The phenylcyclohexylcarboxamides, some of which are known, are suitable as active compounds in medicaments, in particular in medicaments for the treatment of restenosis.Type: GrantFiled: October 24, 1997Date of Patent: August 10, 1999Assignee: Bayer AktiengesellschaftInventors: Matthias Muller-Gliemann, Ulrich Muller, Martin Beuck, Siegfried Zaiss, Christoph Gerdes, Anke Domdey-Bette, Rudi Grutzmann, Stefan Lohmer, Stefan Wohlfeil, Ozkan Yalkinoglu, James Elting, Dirk Denzer
-
Patent number: 5627285Abstract: Sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be prepared by reacting sulphonylbenzyl-substituted aldehydes with appropriate CH-acidic compounds and then dehydrating.The sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be used in medicaments, in particular for the treatment of high blood pressure and atherosclerosis.Type: GrantFiled: September 6, 1995Date of Patent: May 6, 1997Assignee: Bayer AktiengesellschaftInventors: Rudolf Hanko, J urgen Dressel, Peter Fey, Walter H ubsch, Thomas Kr amer, Ulrich E. M uller, Matthias M uller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu
-
Patent number: 5607962Abstract: Substituted indole derivatives are prepared by reacting appropriate carboxylic acids, if appropriate in the presence of auxiliaries, with appropriate amines. The substituted indole derivatives are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and restenosis.Type: GrantFiled: January 25, 1996Date of Patent: March 4, 1997Assignee: Bayer AktiengesellschaftInventors: Matthias M uller-Gliemann, Ulrich M uller, Martin Beuck, Siegfried Zaiss, Christoph Gerdes, Anke Domdey-Bette, Rudi Gr utzmann, Stefan Lohmer, Stefan Wohlfeil, Ozkan Yalkinoglu, James Elting, Dirk Denzer
-
Patent number: 5475016Abstract: Sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be prepared by reacting sulphonylbenzyl-substituted aldehydes with appropriate CH-acidic compounds and then dehydrating.The sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be used in medicaments, in particular for the treatment of high blood pressure and atherosclerosis.Type: GrantFiled: February 18, 1993Date of Patent: December 12, 1995Assignee: Bayer AktiengesellschaftInventors: Rudolf Hanko, Jurgen Dressel, Peter Fey, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Matthias Muller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu
-
Patent number: 5420149Abstract: Imidazolyl-substituted phenylacetic acid derivatives are prepared by first reacting suitably substituted phenylacetic acid with imidazoles and subsequently converting the product into an amide. The compounds can be employed as active compounds in medicaments, in particular for treating hypertension and atherosclerosis.Type: GrantFiled: March 3, 1993Date of Patent: May 30, 1995Assignee: Bayer AktiengesellschaftInventors: Ulrich E. Muller, Matthias Muller-Gliemann, Jurgen Dressel, Peter Fey, Rudolf Hanko, Walter Husch, Thomas Kramer, Martin Beuck, Stanislav Kazda, Stefan Wohlfeil, Ozkan Yalkinoglu, Andreas Knorr, Johannes-Peter Stasch, Ulrich Niewohner
-
Patent number: 5364942Abstract: Sulphonylbenzyl-substituted imidazopyridines can be prepared by reacting correspondingly substituted imidazopyridines with sulphonylbenzyl compounds. The sulphonylbenzyl-substituted imidazopyridines can be employed as active compounds in medicaments, in particular for the treatment of hypertension and atherosclerosis.Type: GrantFiled: February 18, 1993Date of Patent: November 15, 1994Assignee: Bayer AktiengesellschaftInventors: Rudolf Hanko, Jurgen Dressel, Peter Fey, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Matthias Muller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu
-
Patent number: 5352687Abstract: Substituted phenylacetamides can be prepared by reaction of appropriately substituted phenylacetic acids with imidazoles and subsequent amidation. The substituted phenylacetic acid derivatives can be employed in medicaments for the treatment of high blood pressure and atherosclerosis.Type: GrantFiled: March 3, 1993Date of Patent: October 4, 1994Assignee: Bayer AktiengesellschaftInventors: Ulrich E. Muller, Matthias Muller-Gliemann, Jurgen Dressel, Peter Fey, Rudolf Hanko, Walter Hubsch, Thomas Kramer, Martin Beuck, Stanislav Kazda, Stefan Wohlfeil, Ozkan Yalkinoglu, Andreas Knorr, Johannes-Peter Stasch
-
Patent number: 5318980Abstract: Sulphonylbenzyl-substituted imidazoles can be prepared by first reacting imidazolylaldehydes with sulphonylbenzyl compounds and then oxidising or reducing the aldehyde function in the customary manner.The sulphonylbenzyl-substituted imidazoles can be used as active compounds in medicaments.Type: GrantFiled: February 18, 1993Date of Patent: June 7, 1994Assignee: Bayer AktiengesellschaftInventors: Rudolf Hanko, Jurgen Dressel, Peter Fey, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Matthias Muller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu